Mutations in signalling genes such as FLT3, which lead to constitutive activation of the receptor tyrosine kinase, confer survival and proliferative advantage to cells.3,9FMS-related tyrosine kinase 3 mutations occur in approximately one-third of patients with AML, and the ITD mutation is considered the second most common molecular abnormality in CN-AML (28% – 34% of cases).4,9FMS-related tyrosine kinase 3-ITD mutations usually occur between exons 14 and 15 and can range between 3 bp and more than 400 bp in size.11 This evidence concerns the gene FER and acute myeloid leukemia.